This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Aripiprazole Augmentation of Clomipramine-Refractory Obsessive-Compulsive Disorder

Serge Friedman, MD; Tania Abou Abdallah, MD; Mohamed Oumaya, MD; Frédéric Rouillon, MD; and Julien-Daniel Guelfi, MD

Published: June 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Antipsychotic augmentation strategy is relevant in obsessive-compulsive disorder (OCD), as half of patients fail to respond to an initial adequate trial of serotonin reuptake inhibitors.1 Aripiprazole is an antipsychotic drug that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors. The drug is also a serotonin 5-HT2A receptor antagonist that might be of therapeutic value in OCD, as suggested by an open-label aripiprazole monotherapy study.2

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: